** Shares of Maryland-based vaccine maker Novavax NVAX.O up 1.6% at $7.44 premarket
** Company posts Q4 adj loss of 51 cents per share vs adj loss of $1.44 per share a year ago, as it ramps down spending on COVID vaccines, its only product on market
** Co signed a licensing deal worth at least $1.2 billion with French drugmaker SanofiSASY.PA in May to hand over the rights to sell its vaccines in several markets, including the U.S. and Europe
** NVAX reports quarterly sales of $88.3 million, beating analysts' avg estimate of $84.4 million - data compiled by LSEG
** Quarterly sales of COVID vaccines came in at $49.8 million, down 80.2% from a year earlier
** NVAX has risen 33% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。